214 results match your criteria: "United Kingdom (V.N.); andBoyce Thompson Institute for Plant Science[Affiliation]"

Background: Females with hypertrophic cardiomyopathy present at a more advanced stage of the disease and have a higher risk of heart failure and death. The factors behind these differences are unclear. We aimed to investigate sex-related differences in clinical and genetic factors affecting adverse outcomes in the Sarcomeric Human Cardiomyopathy Registry.

View Article and Find Full Text PDF

Purpose: Transurethral resection of bladder tumor (TURBT) is the initial staging procedure for new bladder cancers (BCs). For muscle-invasive bladder cancers (MIBCs), TURBT may delay definitive treatment. We investigated whether definitive treatment can be expedited for MIBC using flexible cystoscopic biopsy and multiparametric magnetic resonance imaging (mpMRI) for initial staging.

View Article and Find Full Text PDF

Transcatheter aortic valve implantation (TAVI) is a safe and effective procedure for the treatment of aortic stenosis. With the recently broadened indications, there is a larger cohort of patients likely to outlive their first transcatheter heart valve (THV). This review discusses relevant lifetime planning considerations, focusing on the utility of preprocedural computed tomography imaging to help implanters future-proof their patients who are likely to outlive their first valve.

View Article and Find Full Text PDF

Low Penetrance Sarcomere Variants Contribute to Additive Risk in Hypertrophic Cardiomyopathy.

Circulation

December 2024

Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan, Ann Arbor. (E.D.S., Y.-C.T., B.E., A.B., O.M., S.S., A.S.H.).

Article Synopsis
  • - Hypertrophic cardiomyopathy (HCM) was traditionally seen as caused by rare, high-risk single-gene changes, but new research indicates common low-risk variants (LowSVs) also play a significant role in the disease.
  • - In a study of over 6000 patients, 12 LowSVs were discovered, which are relatively common in the general population and more prevalent in HCM patients, suggesting they may influence disease severity and risk.
  • - While LowSVs alone are linked to a later onset of HCM and fewer complications, their presence alongside more severe genetic variants increases health risks significantly.
View Article and Find Full Text PDF
Article Synopsis
  • Small studies suggest that low-dose oral minoxidil (LDOM) might be effective and safe for hair loss, but more extensive research and guidelines are needed.* -
  • An expert consensus statement was developed involving 43 dermatologists to standardize LDOM prescribing practices, covering various aspects like indications, dosing, and monitoring.* -
  • The consensus reached includes 76 relevant points, but topics related to pediatric use and titration protocols need further investigation, highlighting gaps in research for younger patients.*
View Article and Find Full Text PDF

Background: Redo-transcatheter aortic valve implantation (TAVI) may be unfeasible because of the risk of compromising coronary flow or coronary access by the pinned back leaflets of the index transcatheter aortic valve.

Aims: We aimed to evaluate the feasibility of redo-TAVI using the balloon-expandable SAPIEN 3 (S3) implanted within the self-expanding ACURATE neo2 (ACn2) valve and to identify predictors associated with a high risk of compromising coronary flow.

Methods: A total of 153 post-ACn2 TAVI cardiac computed tomography scans were analysed.

View Article and Find Full Text PDF

Preclinical Profile of the HIV-1 Maturation Inhibitor VH3739937.

Viruses

September 2024

ViiV Healthcare, 36 East Industrial Road, Branford, CT 06405, USA.

The HIV-1 maturation inhibitor (MI) VH3739937 (VH-937) inhibits cleavage between capsid and spacer peptide 1 and exhibits an oral half-life in humans compatible with once-weekly dosing. Here, the antiviral properties of VH-937 are described. VH-937 exhibited potent antiviral activity against all HIV-1 laboratory strains, clinical isolates, and recombinant viruses examined, with half-maximal effective concentration (EC) values ≤ 5.

View Article and Find Full Text PDF
Article Synopsis
  • An error grid is a tool that helps compare glucose levels measured by devices to see if they are correct and to identify any risks.
  • Experts created a new error grid called the DTS Error Grid that works for both blood glucose monitors (BGMs) and continuous glucose monitors (CGMs), organizing accuracy into five risk zones.
  • The results showed that the DTS Error Grid provides a clearer picture of how accurate these devices are and includes a separate matrix to evaluate how well CGMs track glucose trends over time.
View Article and Find Full Text PDF
Article Synopsis
  • Artificial intelligence (AI) can significantly enhance drug discovery processes by effectively integrating various biological data, which helps in predicting drug target properties and understanding disease mechanisms.
  • There are ongoing challenges in using AI for drug target discovery, such as addressing data biases, ensuring model interpretability, and validating predicted targets.
  • This review highlights recent advancements in AI applications for drug target discovery and discusses future possibilities, aiming to improve the development of new and safer medications.
View Article and Find Full Text PDF
Article Synopsis
  • An online survey of European thyroid specialists revealed that 28% believe thyroid hormone (TH) treatment may be appropriate for euthyroid patients with growing simple goiters, despite guidelines against this practice.
  • There were significant regional differences in support for TH treatment, with only 7% in The Netherlands compared to 78% in the Czech Republic.
  • Factors influencing the likelihood of recommending TH included the specialist's age and the historical iodine insufficiency of their region, while gender, country, and economic factors showed weak associations.
View Article and Find Full Text PDF

Transcatheter Valve Repair in Heart Failure with Moderate to Severe Mitral Regurgitation.

N Engl J Med

November 2024

From the Department of Cardiology of German Heart Center Charité and the Institute of Health Center for Regenerative Therapies, German Center for Cardiovascular Research (DZHK) Partner Site Berlin, Charité Universitätsmedizin (S.D.A., M.D., W.H.), the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charité, Campus Benjamin Franklin, the Berlin Institute of Health, and DZHK Partner Site Berlin (U.L.), Deutsches Herzzentrum der Charité, the Department of Cardiology, Angiology, and Intensive Care Medicine, Campus Charité Mitte, the Center for Cardiovascular Telemedicine, and DZHK Partner Site Berlin, Charité Universitätsmedizin (F.K.), Berlin, the Departments of Cardiology and Pneumology (S.D.A., M.D., G.H., W.S.) and Medical Statistics (T.F., M.P.) and the Clinical Trial Unit (J.H.), University Medical Center Göttingen, and the Heart Center, Department of Cardiology (W.S.), Georg August University of Göttingen, DZHK Partner Site Göttingen, Göttingen, the Department of Cardiology, University Medical Center of the Johannes Gutenberg-University Mainz (R.S.B., M. Geyer, T.F.R.), Mainz, the Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital Düsseldorf, Medical Faculty of the Heinrich Heine University Düsseldorf, and Cardiovascular Research Institute Düsseldorf, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf (M. Kelm), the Department of Rhythmology, University Heart Center Lübeck, University Hospital Schleswig-Holstein, Lübeck (K.-H.K.), the West German Heart and Vascular Center, Department of Cardiology and Vascular Medicine, University Hospital Essen, University Duisburg-Essen, Essen (T.R.), the Heart and Vascular Center, Bad Bevensen (U.S.), the Department of Internal Medicine I, Cardiology, University Hospital Jena, Jena (P.C.S.), the Institute for Cardiovascular Regeneration, Goethe University Frankfurt, and DZHK Partner Site Rhein-Main, Frankfurt am Main (A.Z.), the Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, and DZHK Partner Site Hamburg-Kiel-Lübeck, Hamburg (M. Karakas), the Department of Cardiology, Rostock University Medical Center, Rostock (A.Ö.), the Department of Medicine, Heart and Vascular Center, Division of Cardiology and Vascular Medicine, Johanniter Hospital Stendal, Stendal (M. Gross), the Mid-German Heart Center, Department of Cardiology, Angiology, and Intensive Care Medicine, University Hospital Halle, Halle (J.T.) - all in Germany; the Department of Medicine, University of Mississippi Medical Center, Jackson (J.B.); Baylor Scott and White Research Institute, Dallas (J.B., M.S.K.), Baylor Scott and White the Heart Hospital Plano, Plano (M.S.K.), and the Department of Medicine, Baylor College of Medicine, Temple (M.S.K.) - all in Texas; the Department of Translational Medicine, University of Ferrara, Ferrara (R.F.), the Cardiac Surgery Unit, IRCCS San Raffaele Scientific Institute, Milan (O.A.), ANMCO Associazione Nazionale Medici Cardiologi Ospedalieri Research Center, Heart Care Foundation, Florence (A.P.M.), and the Institute of Cardiology, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, and the Department of Medical and Surgical Specialties, Radiologic Sciences and Public Health, University of Brescia, Brescia (M.M., M.A.) - all in Italy; the Division of Cardiovascular Medicine, Ohio State University, Columbus (W.T.A.); the Department of Cardiology, Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Lugano (A.A.), and the Center for Translational and Experimental Cardiology, Department of Cardiology, University Hospital Zurich, University of Zurich, Zurich (F.R.) - both in Switzerland; the Heart Institute, Hospital Universitari Germans Trias i Pujol, Barcelona (A.B.-G., E.S.-V.), and the Department of Cardiology, Hospital Universitario Ramón y Cajal, and Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Instituto de Salud Carlos III, Madrid (J.L.Z.) - all in Spain; the School of Cardiovascular and Metabolic Health, University of Glasgow, British Heart Foundation Glasgow Cardiovascular Research Centre, Glasgow, United Kingdom (J.G.F.C., M.C.P.); the Department of Cardiology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens (G.F.), and the Department of Transcatheter Heart Valves, Hygeia Hospital (K.S., M.C., P.K., K.P.), Athens, and the Department of Cardiology, St. Luke's Hospital (N.M., E.K.T.), and the European Interbalkan Medical Center (V.N., I.N., K.P.), Thessaloniki - all in Greece; the Department of Cardiology, Copenhagen University Hospital-Rigshospitalet, Copenhagen (F.G.); Unité Formation et Recherche Médecine, Université de Paris-Cité, site Bichat, Laboratoire de Recherche Vasculaire Translationnelle, INSERM, Groupe Hospitalier Bichat, Paris (A.V.); the Division of Cardiology, General Hospital Murska Sobota, Murska Sobota, and the Faculty of Medicine, University of Ljubljana, Ljubljana - both in Slovenia (M.L.); the Division of Cardiology and Structural Heart Diseases (G.S., W.W.) and the Department of Cardiology, Congenital Heart Diseases, and Electrotherapy (Z.K.), Medical University of Silesia, Katowice, the Institute of Heart Diseases, Medical University and University Hospital, Wrocław (K.R., P.P.), and the Department of Interventional Cardiology, Department of Radiology and Diagnostic Imaging, John Paul II Hospital, Krakow (Ł.W.) - all in Poland; and Centro Academico de Medicina de Lisboa, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal (F.J.P.).

Article Synopsis
  • The study examined the effectiveness of transcatheter mitral-valve repair in patients suffering from heart failure and functional mitral regurgitation, comparing it to standard medical therapy.
  • In a trial with 505 patients, results showed that those who received the device had significantly lower rates of hospitalizations for heart failure and cardiovascular death compared to those who only received medical therapy.
  • Additionally, patients in the device group experienced a greater improvement in health status, as measured by the Kansas City Cardiomyopathy Questionnaire, indicating better outcomes with the transcatheter procedure.
View Article and Find Full Text PDF

Perioperative extracorporeal membrane oxygenation in liver transplantation-bridge to transplantation, intraoperative salvage, and postoperative support: outcomes and predictors for survival in a large-volume liver transplant center.

Am J Transplant

September 2024

Liver Intensive Care, General Intensive Care & ECMO, Liver Intensive Therapy Unit, King's College Hospital, London, United Kingdom; Critical Care, Anesthesia & Pain Institute, Cleveland Clinic London, London, United Kingdom.

Data on perioperative extracorporeal membrane oxygenation (ECMO) in liver transplantation (LT) are scarce. ECMO has been used preoperatively, intraoperatively, and postoperatively for a variety of indications at our center. This retrospective, single-center study of ECMO use peri-LT aimed to describe predictors for successful outcome in this highly select cohort of patients.

View Article and Find Full Text PDF

Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women.

N Engl J Med

October 2024

From the Desmond Tutu HIV Centre (L.-G.B., K.G., G.N., Y.S.) and the Department of Medicine, Vuka Research Clinic (A.M.W.), University of Cape Town, Cape Town, the Department of Epidemiology and Prevention, Centre for the AIDS Programme of Research in South Africa (Q.A.K.), Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal (I.H., L.E.M., D.M., M.N., D.P.), the Department of Obstetrics and Gynaecology, Wits Maternal, Adolescent, and Child Health Research Unit, University of the Witwatersrand (M.J.), Africa Health Research Institute (L.L.), and the HIV and Other Infectious Diseases Research Unit, South African Medical Research Council (V.N., L.N., S.P., N.S., E.S.), Durban, Setshaba Research Centre, Tshwane City (K.A.), the Department of Medical Microbiology, School of Medicine, Faculty of Health Sciences, University of Pretoria (K.A.), and the Aurum Institute, Pretoria Clinical Research Site (Z.Z.), Pretoria, the Foundation for Professional Development, Ndevana Community Research Site (J.B.), and Synergy Biomed Research Institute (M. Malahleha), East London, the Clinical Research Division, the Aurum Institute, Rustenburg (W.B.), Qhakaza Mbokodo Research Clinic (P.K.) and La Verna Hospital (P.K.), Ladysmith, Madibeng Centre for Research, Brits (C.E.L.), the Aurum Institute (M. Manentsa) and Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, School of Public Health, University of the Witwatersrand (N.N., T.P.-P.), Johannesburg, the Perinatal HIV Research Unit, Kliptown-Aeroton Clinical Research Site, University of the Witwatersrand, Soweto (R.P.), and the Aurum Institute, Klerksdorp Clinical Research Site, Klerksdorp (P.S.) - all in South Africa; Gilead Sciences, Foster City, CA (M.D., R.E., Y.Z., A.K., C.C.C., J.M.B.); the Department of Epidemiology, Columbia University Mailman School of Public Health, New York (Q.A.K.); the Department of Medicine, Vanderbilt University, Nashville (W.B.); Africa Medical and Behavioral Sciences Organization, Kalisizo (G.K.), the Department of Epidemiology and Biostatistics, Makerere University School of Public Health (N.K., F.M.K.), and Makerere University-Johns Hopkins University Research Collaboration (F.M.K.), Kampala - all in Uganda; the Department of Epidemiology, School of Public Health, University of Washington, Seattle (T.P.-P.); and Gilead Sciences, Cambridge, United Kingdom (C.D.).

Background: There are gaps in uptake of, adherence to, and persistence in the use of preexposure prophylaxis for human immunodeficiency virus (HIV) prevention among cisgender women.

Methods: We conducted a phase 3, double-blind, randomized, controlled trial involving adolescent girls and young women in South Africa and Uganda. Participants were assigned in a 2:2:1 ratio to receive subcutaneous lenacapavir every 26 weeks, daily oral emtricitabine-tenofovir alafenamide (F/TAF), or daily oral emtricitabine-tenofovir disoproxil fumarate (F/TDF; active control); all participants also received the alternate subcutaneous or oral placebo.

View Article and Find Full Text PDF

Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer.

N Engl J Med

July 2024

From Universitaire Ziekenhuizen Leuven, Katholieke Universiteit Leuven, and the Belgium and Luxembourg Gynaecological Oncology Group, Leuven (I.V., E.V.N.), and Centre Hospitalier Universitaire de Liège, Liege (C.G.) - all in Belgium; Cancer Center Clínica Universidad de Navarra (A.G.-M.), Hospital Universitario 12 de Octubre (L.M.), and Grupo Español de Investigación en Cáncer de Ovario (GEICO) (A.G.-M.), Madrid, and Gynecologic Cancer Program, Vall d'Hebron Institute of Oncology, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona (A.O.) - all in Spain; Saitama Medical School International Medical Center, Saitama (K.F., K.H.), and the National Cancer Center Hospital, Tokyo (K.Y.) - both in Japan; Centre Hospitalier Universitaire de Besançon, Besançon (E.K.), and GINECO (E.K., A.A.) and Groupe Hospitalier Diaconesses Croix Saint-Simon (A.A.), Paris - all in France; Országos Onkológiai Intézet, Budapest, Hungary (A.B.); Georgia Cancer Center, Augusta University, Augusta (S.G.); Yonsei University College of Medicine (J.-Y.L.) and Samsung Medical Center, Sungkyunkwan University School of Medicine (B.-G.K.) - both in Seoul, South Korea; the Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London (S.B.), and the Christie NHS Foundation Trust, Clinical Oncology, Manchester (L.B.) - both in the United Kingdom; Hospital Beneficencia Portuguesa de São Paulo (F.C.M.), Hospital Israelita Albert Einstein de São Paulo (F.C.M.), and Instituto Brasileiro de Controle do Câncer (F.M.C.) - all in Sao Paulo; Fondazione Policlinico Gemelli IRCCS and Catholic University of Sacred Heart, Rome (D.L.); Arbeitsgemeinschaft Gynäkologische Onkologie Study Group and University Medical Center Hamburg-Eppendorf, Hamburg, Germany (L.W.); Amsterdam University Medical Centers, Amsterdam (A.W.); Sunnybrook Research Institute, Toronto (A.C.); Medica Oncólogia Clinica en Grupo Gamma, Rosario, Argentina (M.R.); Skåne University Hospital and Lund University, Lund, Sweden (M.B.); First Faculty of Medicine, Charles University, General University Hospital in Prague, Prague, Czech Republic (D.C.); Pfizer, Bothell, WA (L.N., M.S.L.T., E.W.); Genmab US, Princeton, NJ (I.S.); and Mount Sinai Medical Center, Miami Beach, FL (B.M.S.).

Article Synopsis
  • Recurrent cervical cancer poses serious health risks, especially after initial treatment, leading to the need for new therapy options.
  • A phase 3 trial compared the effects of tisotumab vedotin to standard chemotherapy in 502 patients with recurrent or metastatic cervical cancer, focusing on overall survival.
  • Results show that tisotumab vedotin significantly improved median overall survival (11.5 months vs. 9.5 months) and progression-free survival (4.2 months vs. 2.9 months), with a higher response rate compared to chemotherapy, despite both groups experiencing a high incidence of adverse events.
View Article and Find Full Text PDF

Background: Hs-cTnT (cardiac troponin T measured with a highly sensitive assay) and NT-proBNP (N-terminal pro-B-type natriuretic peptide) may identify adults with hypertension who derive greater cognitive benefits from lower systolic blood pressure targets.

Methods: In the SPRINT (Systolic Blood Pressure Intervention Trial) MIND study, participants were categorized as having both hs-cTnT and NT-proBNP in the lower 2 tertiles (n=4226), one in the highest tertile (n=2379), and both in the highest tertile (n=1506). We assessed the effect of intensive versus standard treatment on the composite of mild cognitive impairment (MCI) or probable dementia (PD) across biomarker categories.

View Article and Find Full Text PDF

Multisite Validation of a Functional Assay to Adjudicate Brugada Syndrome-Associated Variants.

Circ Genom Precis Med

August 2024

Vanderbilt Center for Arrhythmia Research and Therapeutics (Van-CART), Department of Medicine, Vanderbilt University Medical Center, Nashville, TN (J.F.S., G.D., M.B.S., D.M.R., A.M.G.).

Background: Brugada syndrome is an inheritable arrhythmia condition that is associated with rare, loss-of-function variants in . Interpreting the pathogenicity of missense variants is challenging, and ≈79% of missense variants in ClinVar are currently classified as variants of uncertain significance. Automated patch clamp technology enables high-throughput functional studies of ion channel variants and can provide evidence for variant reclassification.

View Article and Find Full Text PDF

Impact of mutations in SARS-CoV-2 recombinant sub-variant XBB.1.16 on the binding affinity with human ACE2 receptor.

J Mol Graph Model

September 2024

Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, 75270, Pakistan. Electronic address:

Despite the waning threat of the COVID-19 pandemic, its detrimental impact on global health persists. Regardless of natural immunity or immunity obtained through vaccination, emerging variants of the virus continue to undergo mutations and propagate globally. The persistent mutations in SARS-CoV-2, along with the subsequent formation of recombinant sub-variants has become a challenge for researchers and health professionals, raising concerns about the efficacy of current vaccines.

View Article and Find Full Text PDF

Gene-Gene Interaction Between Factor- and Genes in Cerebral Venous Thrombosis: The BEAST Study.

Neurology

June 2024

From the Institute of Cardiovascular Research Royal Holloway (G.K.-D., P.S.), University of London (ICR2UL), United Kingdom; Fondazione IRCCS Ca'Granda-Ospedale Maggiore Policlinico (I.M., S.M.P., M.A., P.B., E.P.), A. Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy; Moncucco Hospital Group (I.M., E.G.), Lugano, Switzerland; Atherosclerosis and Thrombosis Unit (E.G., G.F., D.C.), I.R.C.C.S. Fondazione "Casa Sollievo della Sofferenza", S. Giovanni Rotondo; Medical and Surgical Department (E.G.), University of Foggia, Italy; Department of Obstetrics (E.G.), Gynaecology and Perinatal Medicine, First Sechenov University, Moscow, Russia; Neurology (S.H., J.P., E.H., T.T.), Helsinki University Hospital and University of Helsinki, Finland; Department of Clinical Neuroscience (E.L., K.J., T.T.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg; Department of Neurology (E.L., K.J., T.T.), Sahlgrenska University Hospital, Gothenburg, Sweden; Medical Genetics (M. Margaglione, R.S.), Department of Clinical and Experimental Medicine, University of Foggia, Italy; Normandy University (V.L.C.D.), UNIROUEN, INSERM U1096, Rouen University Hospital, Vascular Hemostasis Unit and INSERM CIC-CRB 1404; Department of Neurology (A.B.T.), Rouen University Hospital, France; Neurology Unit (M.Z.), Stroke Unit, Azienda Unità Sanitaria Locale-IRCCS of Reggio Emilia; Department of Clinical and Experimental Medicine (M. Mancuso), Neurological Institute, University of Pisa, Italy; UMC Utrecht Brain Center (Y.M.R.), Department of Neurology and Neurosurgery, University Medical Center Utrecht, the Netherlands; Department of Neurology (B.B.W.), University of Virginia, Charlottesville, VA; Department of Neurology (J.J.M., A.T.), University of Utah, Salt Lake City; Department of Neurology (S.Z., M.C.B., J.M.C.), Amsterdam University Medical Centers, location AMC, Amsterdam Neuroscience, University of Amsterdam, the Netherlands; Department of Neurosciences (R.L.), Experimental Neurology, KU Leuven-University of Leuven; VIB Center for Brain & Disease Research; Department of Neurology, University Hospitals Leuven, Belgium; Department of Pathophysiology and Transplantation (E.P.), Università degli Studi di Milano, Milan; Department of Clinical and Experimental Sciences (P. Costa), Neurology Clinic; Division of Biology and Genetics (M.C.), Department of Molecular and Translational Medicine, University of Brescia, Italy; Stroke Center (D.A.D.S.), Centro Hospitalar Universitário Lisboa Central; CEEM and Institute of Anatomy (D.A.D.S.), Faculdade de Medicina; Instituto de Medicina Molecular João Lobo Antunes (D.A.D.S., J.M.F.), Universidade de Lisboa; Department of Neurosciences (S.G.R., P. Canhao), Hospital of Santa Maria, University of Lisbon, Portugal; Stroke Clinic (A.A.), National Institute of Neurology and Neurosurgery Manuel Velasco Suarez, Mexico City; Department of Neurology (K.S.), University of Athens School of Medicine, Eginition Hospital, Athens, Greece; McMaster University (A.H., R.D., G.P.), Pathology and Molecular Medicine, Population Health Research Institute and Thrombosis and Atherosclerosis Research Institute, Hamilton Health Sciences, Hamilton, Ontario, Canada; Department of Medicine and Surgery (A.P.), University of Parma, Stroke Care Program, Department of Emergency, Parma University Hospital, Italy; Stroke Division (V.N.T.), Florey Institute of Neuroscience and Mental Health, University of Melbourne, Heidelberg, Victoria, Australia; and Department of Clinical Neuroscience (P.S.), Imperial College Healthcare NHS Trust, London, United Kingdom.

Article Synopsis
  • Gene-gene interactions are believed to play a significant role in the development of multifactorial diseases like cerebral venous thrombosis (CVT), highlighting potential causes of unexplained heritability.
  • A study involving 882 CVT patients and 1,205 control participants found that specific gene variants significantly increased the likelihood of developing CVT, particularly when individuals had certain blood types.
  • The research concluded that the interactions between specific genes could raise the risk of CVT by as much as 14 times, underscoring the importance of understanding these genetic factors in disease etiology.
View Article and Find Full Text PDF
Article Synopsis
  • Critically ill children with respiratory infections often have undetermined microbiological causes, but molecular diagnostic arrays present a promising solution for faster identification of pathogens.
  • Three cases in a pediatric intensive care unit showcased the effectiveness of a 52 pathogen TaqMan array card (TAC) in diagnosing bacterial and fungal infections, leading to quicker and more accurate diagnoses compared to traditional methods.
  • These findings suggest that using molecular arrays, along with team interpretation, can significantly improve early pathogen-specific diagnoses in pediatric intensive care settings.
View Article and Find Full Text PDF

This research work deals with the examination of the techno-economic, exergy, and energy analyses of biomass gasification of the invasive weed (PHP) using Steam - Carbon dioxide (CO) as a gasifying agent with the support of simulation modeling for sustainable energy conversion process. The aim of this work is to simulate the gasification process through consideration of the impacts of various operating factors on gasification. This study attains the gradual increase in hydrogen (H) concentration from 51% to 63% along with the rise in carbon monoxide (CO) from 14.

View Article and Find Full Text PDF
Article Synopsis
  • T-cell responses require two signals for effective activation: engagement of T-cell receptors (signal 1) and additional costimulatory signals (signal 2), which T-cell bispecific antibodies (TCBs) can provide by targeting specific antigens and CD3ε.
  • The study introduces CD19-CD28, a bispecific CD19-targeted CD28 agonist, designed to enhance the effectiveness of glofitamab, a TCB targeting malignant B cells, by delivering the crucial costimulatory signal 2 needed for stronger T-cell responses.
  • Initial results show that combining glofitamab with CD19-CD28 and the 4-1BB agonist significantly improves long
View Article and Find Full Text PDF
Article Synopsis
  • The search for biomarkers that measure biological aging, especially 'omic'-based ones, has gained momentum, aiming to predict aging outcomes and assess interventions for healthy aging.
  • There is currently no agreement on the best methods to validate these aging biomarkers before using them in clinical settings.
  • The review emphasizes the need for systematic validation, which can enhance the reliability and effectiveness of aging biomarkers in clinical research and trials focused on longevity.
View Article and Find Full Text PDF

Effect of Body Mass Index on Effectiveness of CT versus Invasive Coronary Angiography in Stable Chest Pain: The DISCHARGE Trial.

Radiology

February 2024

School of Cardiovascular and Metabolic Health, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom (R.S., D.C., C.B., C.D.); Golden Jubilee National Hospital, Clydebank, United Kingdom (D.C., C.B.); Heart and Vascular Center, Semmelweis University, Budapest, Hungary (B.M., P.M.H., T. Bárány, B.S., M.V.N.); Departments of Cardiology (K.F.K., A.D.K.) and Radiology (K.F.K., A.D.K.), Copenhagen University Hospital-Rigshospitalet & Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Cardiology, Southeastern Health and Social Care Trust, Belfast, United Kingdom (P.D., C.O., S. Kelly, S.R.); Department of Cardiology, Hospital Universitario Vall d'Hebron, Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain (J.R.P., F.X.V., B.G.d.B.); Centro de Investigación Biomédica en Red, Madrid, Spain (J.R.P., F.X.V., B.G.d.B.); Department of Cardiology, Paul Stradins Clinical University Hospital, Riga, Latvia (A.E.); University of Latvia, Riga, Latvia (A.E.); Department of Cardiology, Motol University Hospital, Prague, Czech Republic (J.V., M.H.); Department of Cardiology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania (G.Š.); Department of Cardiology, Hospital of Lithuanian University of Health Sciences, Kaunas, Lithuania (G.Š.); Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia (N.Č.A., F.A.); Department of Cardiology, Institute for Cardiovascular Diseases of Vojvodina, Novi Sad, Serbia (N.Č.A., F.A.); Department of Radiology, University of Leipzig Heart Centre, Leipzig, Germany (M.G.); Department of Radiology, St. Vincent's University Hospital, Dublin, Ireland (J.D.D.); School of Medicine, University College Dublin, Dublin, Ireland (J.D.D.); Department of Cardiology, Basurto Hospital, Bilbao, Spain (I.D., A.R.); Departments of Cardiology (G.D.) and Radiology (E.T.), Aintree University Hospital, Liverpool, United Kingdom; Edge Hill University, Ormskirk, United Kingdom (G.D.); Department of Radiology, Charité-Universitätsmedizin Berlin Campus Mitte, Charitéplatz 1, Freie Universität Berlin and Humboldt-Universität zu 10117 Berlin, Germany (E.Z., S.F., M. Mohamed, M.R., V.W., M.E., M.B., M.D.); National Institute of Cardiology, Warsaw, Poland (C. Kępka, M.K.); Department of Cardiology, Internal Medicine Clinic, Clinical Hospital Center Zemun, Belgrade, Serbia (R.V., A.Z.); Faculty of Medicine, University of Belgrade, Belgrade, Serbia (R.V.); Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Rome, Italy (M. Francone); Department of Biomedical Sciences, Humanitas University, Milan, Italy (M. Francone); Department of Cardiology, Provincial Specialist Hospital in Wroclaw, Wroclaw, Poland (M.I.S.); Department of Internal Medicine III, Department of Cardiology, Innsbruck Medical University, Innsbruck, Austria (F.P.); Turku PET Centre, Turku University Hospital and University of Turku, Turku, Finland (J.K.); Department of Cardiology, Centro Hospitalar de Vila Nova de Gaia-Espinho, Vila Nova de Gaia, Portugal (R.F., V.G.R.); Department of Cardiology, Alb Fils Kliniken, Göppingen, Germany (S.S., T.D.); Department of Radiology, University of Cagliari, Cagliari, Italy (L.S.); Department of Cardiology, Royal Liverpool University Hospital, Liverpool, United Kingdom (B.R., M. Fisher); Institute for Cardiovascular Medicine and Science, Liverpool Heart and Chest Hospital, Liverpool, United Kingdom (B.R., M. Fisher); Institute of Public Health, Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany (N.R.); ECRIN-ERIC (European Clinical Research Infrastructure Network-European Research Infrastructure Consortium), Paris, France (C. Kubiak); Department of Public Health, Section for Health Services Research, University of Copenhagen, Copenhagen, Denmark (K.S.H.); Bavarian Cancer Registry, Bavarian Health and Food Safety Authority, Munich, Germany (J.M.N.); Department of Radiology, Medical Imaging Center, Semmelweis University, Budapest, Hungary (P.M.H.); Center of Advanced Research in Multimodality Cardiac Imaging, CardioMed Medical Center, Targu Mures, Romania (I.B., I.R.); Department of Radiology, Paul Stradins Clinical University Hospital, Riga, Latvia (L.Z.); Institute of Cardiology, Lithuanian University of Health Sciences, Kaunas, Lithuania (A.J.); Department of Radiology, Kaunas Clinics, Kaunas, Lithuania (A.J.); Department of Cardiology, University of Leipzig Heart Centre, Leipzig, Germany (M.W.); Department of Cardiology, St. Vincent's University Hospital, University College Dublin, Dublin, Ireland (S. Keane); Department of Radiology, Basurto Hospital, Bilbao, Spain (I.L.); Department of Cardiology and Angiology, Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany (M.L., H.D.); Department of Clinical Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy (M. Mancone); Department of Radiology, Provincial Specialist Hospital in Wroclaw, Wroclaw, Poland (D.K.); Department of Radiology, Innsbruck Medical University, Innsbruck, Austria (G.F.); Heart Center, Turku University Hospital and University of Turku, Turku, Finland (M. Pietilä); Administrative Centre, Health Care District of Southwestern Finland, Turku, Finland (M. Pietilä); Department of Radiology, University of Cagliari, Cagliari, Italy (M. Porcu); Faculty of Health and Life Sciences, University of Liverpool, Liverpool, United Kingdom (M. Fisher); Department of Cardiology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark (C.S.); Department of Cardiology, George Emil Palade University of Medicine, Pharmacy, Science and Technology, Tirgu Mures, Romania (R.A.); Section of Cardiology, Department of Medicine, Copenhagen University Hospital of Glostrup, Glostrup, Denmark (J.A.); Department of Radiology, Hospital Universitario Vall d'Hebron, Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain (H.C.C.); Department of Cardiology, Nordsjaellands Hospital, Hillerod, Denmark (B.J.); Department of Internal Medicine, Clinic of Cardiology, George Emil Palade University of Medicine, Pharmacy, Science and Technology, Targu Mures, Romania (R.H., T. Benedek); DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany; Berlin Institute of Health, Berlin, Germany (H.D., M.D.); Berlin University Alliance, Berlin, Germany (M.D.); Department of Clinical Epidemiology and Applied Biostatistics, Universitätsklinikum Tübingen, Tübingen, Germany (L.M.S.H., P.M.); Institute of Biometry and Clinical Epidemiology, Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany (K.N.); Oregon Health & Science University, Portland, Ore (M. Ferencik); County Clinical Emergency Hospital Targu Mures, Targu Mures, Romania (T. Benedek); Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Berlin, Germany (M.D.); and Deutsches Herzzentrum der Charité (DHZC), Berlin, Germany (M.D.).

Background Recent trials support the role of cardiac CT in the evaluation of symptomatic patients suspected of having coronary artery disease (CAD); however, body mass index (BMI) has been reported to negatively impact CT image quality. Purpose To compare initial use of CT versus invasive coronary angiography (ICA) on clinical outcomes in patients with stable chest pain stratified by BMI category. Materials and Methods This prospective study represents a prespecified BMI subgroup analysis of the multicenter Diagnostic Imaging Strategies for Patients with Stable Chest Pain and Intermediate Risk of Coronary Artery Disease (DISCHARGE) trial conducted between October 2015 and April 2019.

View Article and Find Full Text PDF
Article Synopsis
  • The study examined how older men and women are treated for heart attacks (STEMI and NSTEMI) in six countries, focusing on hospitalization rates, intervention procedures, and outcomes from 2011 to 2018.
  • Results showed that while hospitalization rates for heart attacks fell across all countries, the rate ratio of male to female hospitalizations rose, indicating a growing disparity.
  • Females consistently received fewer interventional procedures than males for STEMI across the board, and mortality rates differed, with females often faring worse in STEMI outcomes in most countries but better in NSTEMI outcomes in others.
View Article and Find Full Text PDF

Importance: Current measures of alopecia areata (AA) severity, such as the Severity of Alopecia Tool score, do not adequately capture overall disease impact.

Objective: To explore factors associated with AA severity beyond scalp hair loss, and to support the development of the Alopecia Areata Severity and Morbidity Index (ASAMI).

Evidence Review: A total of 74 hair and scalp disorder specialists from multiple continents were invited to participate in an eDelphi project consisting of 3 survey rounds.

View Article and Find Full Text PDF